LOPRESSOR Drug Patent Profile
✉ Email this page to a colleague
When do Lopressor patents expire, and when can generic versions of Lopressor launch?
Lopressor is a drug marketed by Novartis and Validus Pharms and is included in four NDAs.
The generic ingredient in LOPRESSOR is hydrochlorothiazide; metoprolol tartrate. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; metoprolol tartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOPRESSOR?
- What are the global sales for LOPRESSOR?
- What is Average Wholesale Price for LOPRESSOR?
Summary for LOPRESSOR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Clinical Trials: | 26 |
| Drug Prices: | Drug price information for LOPRESSOR |
| What excipients (inactive ingredients) are in LOPRESSOR? | LOPRESSOR excipients list |
| DailyMed Link: | LOPRESSOR at DailyMed |
Recent Clinical Trials for LOPRESSOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Center for Advancing Translational Science (NCATS) | Phase 2 |
| University of Wisconsin, Madison | Phase 2 |
| Corcept Therapeutics | Phase 1 |
Pharmacology for LOPRESSOR
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for LOPRESSOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LOPRESSOR | metoprolol tartrate | INJECTABLE;INJECTION | 018704-001 | Mar 30, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | LOPRESSOR | metoprolol fumarate | TABLET, EXTENDED RELEASE;ORAL | 019786-003 | Dec 27, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | LOPRESSOR HCT | hydrochlorothiazide; metoprolol tartrate | TABLET;ORAL | 018303-001 | Dec 31, 1984 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | LOPRESSOR | metoprolol fumarate | TABLET, EXTENDED RELEASE;ORAL | 019786-001 | Dec 27, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | LOPRESSOR | metoprolol fumarate | TABLET, EXTENDED RELEASE;ORAL | 019786-002 | Dec 27, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOPRESSOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | LOPRESSOR | metoprolol fumarate | TABLET, EXTENDED RELEASE;ORAL | 019786-004 | Dec 27, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | LOPRESSOR | metoprolol tartrate | INJECTABLE;INJECTION | 018704-001 | Mar 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | LOPRESSOR | metoprolol fumarate | TABLET, EXTENDED RELEASE;ORAL | 019786-003 | Dec 27, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | LOPRESSOR | metoprolol tartrate | INJECTABLE;INJECTION | 018704-001 | Mar 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOPRESSOR
See the table below for patents covering LOPRESSOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1334382 | SYSTEME D'ADMINISTRATION ORALE CONTINUE PAR OSMOSE CONTENANT UN AGENT PHARMACEUTIQUE ACTIF AYANT DES PROPRIETES D'ADHESION DE LA MEMBRANE DU NOYAU AMELIOREES (OSMOTIC CONTINUOUS DISPENSING ORAL DELIVERY SYSTEM CONTAINING A PHARMACEUTICALLY ACCEPTABLE ACTIVE AGENT HAVING IMPROVED CORE MEMBRANE ADHESION PROPERTIES) | ⤷ Sign Up |
| Switzerland | 578507 | ⤷ Sign Up | |
| Netherlands | 7101885 | ⤷ Sign Up | |
| South Africa | 7100682 | ⤷ Sign Up | |
| Philippines | 27150 | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties | ⤷ Sign Up |
| Mexico | 15754 | UN SITEMA PARA SUMINISTRO ORAL DE DISTRIBUCION OSMOTICA Y PROCEDIMIENTO PARA PREPARARLO. | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
